Zanrong Pharmaceutical Technology Co., Ltd. today announced an agreement with Roche to acquire the global rights to ZN-A-1041, an oral small molecule HER2 inhibitor. Zanrong Pharmaceutical is a Chinese biotechnology company focused on developing compounds that can cross the blood-brain barrier. ZN-A-1041 is an oral, selective tyrosine kinase inhibitor targeting human epidermal growth factor receptor 2 (HER2), which is also highly permeable to the blood-brain barrier, making it potentially useful in the treatment of HER2-positive breast cancer Patients with brain metastases and the prevention of brain metastases. Up to 50% of patients with HER2-positive metastatic breast cancer develop brain metastases during the course of the disease. Dr. Cheng Ziqiang, Chairman, CEO and Co-Founder of Zanrong Pharmaceuticals, said: "The strong alliance with Roche can promote the clinical development of ZN-A-1041 more quickly and effectively, and provide HER2-positive breast cancer patients, especially Patients with brain metastases bring new best treatment options. In just five years, we have completed the process from company formation to preclinical independent research and development of products, as well as the first human clinical research, and has been recognized by the well-known multinational pharmaceutical company Roche I believe that with the help of Roche's rich clinical development resources and experience, ZN-A-1041 can be developed and marketed as soon as possible to provide patients with the best treatment options." Dr. Zhou Ding, co-founder and chief scientist of Zanrong Medicine, said: "We We are very pleased that Roche recognized the brain-penetrating innovative drug ZN-A-1041 we designed and developed. This compound has great potential to become the standard treatment for HER2-positive breast cancer in the future." Dr. We are delighted to establish a partnership with Zanrong Medicine, and based on Roche’s deep accumulation in the field of tumors and expertise in HER2-positive breast cancer, we will further develop this innovative drug for HER2-positive breast cancer. Roche has a mission, Committed to driving innovation by combining external innovation with Roche's internal development capabilities to provide patients with unmet therapeutic needs" According to the agreement, Roche will obtain the further development, production and commercialization of ZN-A-1041 worldwide right. To this end, Roche will pay Zanrong Medicine an upfront payment of US$70 million and recent milestone payments, and an additional US$6. $100 million in development and commercialization milestone payments, and future tiered payments based on annual global net sales. About ZN-A-1041 ZN-A-1041 is an oral, selective tyrosine kinase inhibitor targeting HER2 characterized by high blood-brain barrier permeability. At present, the project is conducting phase I clinical research in multiple centers in China and the United States. More data will be revealed at the 2023 ASCO meeting. About Zanrong Pharmaceutical Zanrong Pharmaceutical is a clinical-stage biotechnology company dedicated to the research and development of innovative small molecule tumor drugs. Founded in 2018, the company is headquartered in Suzhou Biobay, and has another research business in Shanghai branch. Zanrong Pharmaceutical uses innovative drug discovery methods and advantages in DMPK to design and develop differentiated "best-in-class" and "first-in-class" drugs. The company focuses on key tumor targets, including ataxia telangiectasia mutated gene (ATM), KRAS G12D and SMARCA2 (BRM), etc. For more information: www.zionpharma.com

Source:zionpharma.com